The U.S. Food and Drug Administration (FDA) has approved expanding the use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to children with cystic fibrosis (CF), ages 6 and older, who have at least one F508del mutation in the CFTR gene or a CFTR mutation that responds to Trikafta in laboratory studies. Use of the triple combination therapy, first approved in […]
Lower levels of certain volatile molecules in the breath of children and adults with cystic fibrosis (CF) can distinguish with good accuracy between those with and without Pseudomonas aeruginosa lung infection, a Dutch study shows. Notably, a reduction in the levels of a single molecule, called ethyl acetate, was a good predictor of P. aeruginosa infection […]
This column is brought to you by anxiety. My anxiety isn’t very nice to me. She knows I need to write a column today, and that it’s the only day I can do it, but also that I have a mile-long to-do list I need to finish quickly. She knows there isn’t really anything “wrong” […]
A combination of bacteria-infecting viruses and antibiotics can be used to effectively protect lung cells against infection by Pseudomonas aeruginosa, a bacteria that commonly causes lung infections in people with cystic fibrosis (CF), according to a study led by researchers at the University of Geneva (UNIGE). The model used to test this therapeutic approach — […]
The U.S. Food and Drug Administration (FDA) has approved expanding the use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to children with cystic fibrosis (CF), ages 6 and older, who have at least one F508del mutation in the CFTR gene or a CFTR mutation that responds to Trikafta in laboratory studies. Use of the triple combination therapy, first approved in […]
Lower levels of certain volatile molecules in the breath of children and adults with cystic fibrosis (CF) can distinguish with good accuracy between those with and without Pseudomonas aeruginosa lung infection, a Dutch study shows. Notably, a reduction in the levels of a single molecule, called ethyl acetate, was a good predictor of P. aeruginosa infection […]
This column is brought to you by anxiety. My anxiety isn’t very nice to me. She knows I need to write a column today, and that it’s the only day I can do it, but also that I have a mile-long to-do list I need to finish quickly. She knows there isn’t really anything “wrong” […]
A combination of bacteria-infecting viruses and antibiotics can be used to effectively protect lung cells against infection by Pseudomonas aeruginosa, a bacteria that commonly causes lung infections in people with cystic fibrosis (CF), according to a study led by researchers at the University of Geneva (UNIGE). The model used to test this therapeutic approach — […]
